Selected article for: "alternative approach and small molecule"
Author: Pollack, Charles V.; Kurz, Michael A.; Hayward, Neil J.
Title: EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report
  • Cord-id: n28ylii6
  • Document date: 2020_9_15
    • ID: n28ylii6
    Snippet: OBJECTIVES: Current approaches to systemic antithrombotic therapy in support of extracorporeal membrane oxygenation are limited and are hampered by both thrombotic and hemorrhagic complications. An alternative approach is needed. DESIGN: Inhibition of coagulation factor XI/activated factor XI is an appealing pathway for antithrombotic support of extracorporeal membrane oxygenation. Selective inhibition of the contact pathway of coagulation could reduce bleeding risk, and because factor XI is lin
    Document: OBJECTIVES: Current approaches to systemic antithrombotic therapy in support of extracorporeal membrane oxygenation are limited and are hampered by both thrombotic and hemorrhagic complications. An alternative approach is needed. DESIGN: Inhibition of coagulation factor XI/activated factor XI is an appealing pathway for antithrombotic support of extracorporeal membrane oxygenation. Selective inhibition of the contact pathway of coagulation could reduce bleeding risk, and because factor XI is linked with the inflammatory and complement systems, it can also be viewed as a biologically plausible target for the prevention of abnormal thrombosis during extracorporeal membrane oxygenation. CONCLUSIONS: We introduce initial information on EP-7041, a parenteral, potent, and selective, small-molecule activated factor XIa inhibitor with pharmacodynamic and pharmacokinetic characteristics that appear well suited for use in a critical care environment.

    Search related documents:
    Co phrase search for related documents
    • active development and low molecular weight: 1
    • active development and lung injury: 1
    • active site and low activity: 1, 2, 3, 4, 5
    • active site and low molecular weight: 1, 2, 3, 4
    • active site and lung injury: 1, 2
    • lmwh low molecular weight heparin and low activity: 1, 2
    • lmwh low molecular weight heparin and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh low molecular weight heparin and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh low molecular weight heparin and lung injury: 1, 2
    • low activity and lung injury: 1, 2, 3
    • low molecular weight and lung injury: 1, 2, 3, 4, 5, 6
    • low molecular weight heparin and lung injury: 1, 2, 3